Lundbeck snaps up Parkinson’s candidate via Prexton buy
Lundbeck has announced plans to buy Prexton Therapeutics in a deal valued at up to 905 million euros.
Read More
Tag: Lundbeck
US clears Lundbeck’s IV epilepsy drug Carnexiv
US regulators have approved Lundbeck’s Carnexiv, the first intravenous formulation of epilepsy drug carbamazepine.
Read More
Lundbeck reveals Alzheimer’s drug trial failure
Lundbeck has announced that the first late-stage trial of its experimental Alzheimer’s disease candidate idalopirdine failed to hit its primary targets.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
